Calcium-channel modulators for cardiovascular disease

Bibliography

• GODFRAIND T: Calcium channel blockers. Birkhaäuser Verla, Basel, Switzerland (2004).
   Google Scholar
• GODFRAIND T, MILLER R, WIBO M: Calcium antagonism and calcium entry blockade. Pharmacol. Rev. (1986) 38(4):321-416.
   PubMed Web of Science ®Google Scholar
• TSIEN RW, ELLINOR PT, HORNE WA: Molecular diversity of voltage-dependent Ca2+ channels. Trends Pharmacol. Sci. (1991) 12:349-354.
   PubMed Web of Science ®Google Scholar
• ERTEL EA, CAMPBELL KP, HARPOLD MM et al.: Nomenclature of voltage-gated calcium channels. Neuron (2000) 25(3):533-535.
   PubMed Web of Science ®Google Scholar
• CATTERALL WA, STRIESSNIG J: Receptor sites for Ca2+ channel antagonists. Trends Pharmacol. Sci. (1992) 13(6):256-262.
   PubMed Web of Science ®Google Scholar
• HOCKERMAN GH, PETERSON BZ, SHARP E, TANADA TN, SCHEUER T, CATTERALL WA: Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-L-type Ca2+ channel. Proc. Natl. Acad. Sci. USA (1997) 94(26):14906-14911.
   PubMed Web of Science ®Google Scholar
• CATTERALL WA: Structure and regulation of voltage-gated Ca2+ channels. Ann. Rev. Cell Dev. Biol. (2000) 16:521-555.
   PubMed Web of Science ®Google Scholar
• MOOSMANG S, LENHARDT P, HAIDER N, HOFMANN F, WEGENER JW: Mouse models to study L-type calcium channel function. Pharmacol. Ther. (2005) 106(3):347-355.
   PubMed Web of Science ®Google Scholar
• MANGONI ME, COUETTE B, BOURINET E, PLATZER J, REIMER D, STRIESSNIG J et al.: Functional role of L-type Cav1.3 Ca2+ channels in cardiac pacemaker activity. Proc. Natl. Acad. Sci. USA (2003) 100(9):5543-5548.
   PubMed Web of Science ®Google Scholar
• SPEDDING M, PAOLETTI R: Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol. Rev. (1992) 44(3):363-376.
   PubMed Web of Science ®Google Scholar
• SCHUSTER A, LACINOVA L, KLUGBAUER N, ITO H, BIRNBAUMER L, HOFMANN F: The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamines. EMBO J. (1996) 15(10):2365-2370.
   PubMed Web of Science ®Google Scholar
• HOCKERMAN GH, JOHNSON BD, ABBOTT MR, SCHEUER T, CATTERALL WA: Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the α1 subunit. J. Biol. Chem. (1997) 272(30):18759-18765.
   PubMed Web of Science ®Google Scholar
• HOCKERMAN GH, DILMAC N, SCHEUER T, CATTERALL WA: Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels. Mol. Pharmacol. (2000) 58(6):1264-1270.
   PubMed Web of Science ®Google Scholar
• HOFMANN F, LACINOVA L, KLUGBAUER N: Voltage-dependent calcium channels: from structure to function. Rev. Physiol. Biochem. Pharmacol. (1999) 139:33-87.
   PubMed Web of Science ®Google Scholar
• STRIESSNIG J: Pharmacology, structure and function of cardiac L-type Ca(2+) channels. Cell Physiol. Biochem. (1999) 9(4-5):242-269.
   PubMed Web of Science ®Google Scholar
• VUAGNAT A, GIACCHE M, HOPKINS PN et al.: Blood pressure response to angiotensin II, low-density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs. J. Mol. Med. (2001) 79(4):175-183.
   PubMed Web of Science ®Google Scholar
• WILLIAMS RR, HUNT SC, HOPKINS PN et al.: Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA (1988) 259(24):3579-3586.
   PubMed Web of Science ®Google Scholar
• BLACK HR, ELLIOTT WJ, GRANDITS G et al.: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 289(16):2073-2082.
   PubMed Web of Science ®Google Scholar
• AGARWAL A, WILLIAMS GH, FISHER ND: Genetics of human hypertension. Trends Endocrinol. Metab. (2005) 16(3):127-133.
   PubMed Web of Science ®Google Scholar
• WILLIAMS GH: Genetic factors associated with volume-sensitive hypertension. Mol. Cell Endocrinol. (2004) 217(1-2):41-44.
   PubMed Web of Science ®Google Scholar
• NABER CK, SIFFERT W: Genetics of human arterial hypertension. Minerva Med. (2004) 95(5):347-356.
   PubMedGoogle Scholar
• IZZO J: Hypertension Primer. Third ed. American Heart Association, Dallas, Texas, USA (2003).
   Google Scholar
• CORVOL P, SOUBRIER F, JEUNEMAITRE X: Molecular genetics of the renin–angiotensin–aldosterone system in human hypertension. Pathol. Biol. (Paris) (1997) 45(3):229-239.
   PubMed Web of Science ®Google Scholar
• BIANCHI G, FERRARI P, STAESSEN JA: Adducin polymorphism: detection and impact on hypertension and related disorders. Hypertension (2005) 45(3):331-340.
   PubMed Web of Science ®Google Scholar
• KEARNEY PM, WHELTON M, REYNOLDS K, MUNTNER P, WHELTON PK, HE J: Global burden of hypertension: analysis of worldwide data. Lancet (2005) 365(9455):217-223.
   PubMed Web of Science ®Google Scholar
• CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42(6):1206-1252.
   PubMed Web of Science ®Google Scholar
• EUROPEAN SOCIETY OF HYPERTENSION-EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES COMMITTEE: 2003 European Society Of Hypertension-European Society Of Cardiology Guidelines For The Management Of Arterial Hypertension. J. Hypertens. (2003) 21(6):1011-1053.
   PubMed Web of Science ®Google Scholar
• ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP. THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288(23):2981-2997.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, MANCIA G: The ALLHAT trial: a verdict or a challenge? J. Hypertens. (2003) 21(2):223.
   PubMed Web of Science ®Google Scholar
• BATH P, CHALMERS J, POWERS W et al.: International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J. Hypertens. (2003) 21(4):665-672.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A: Emerging data on calcium-channel blockers: the COHORT study. Clin. Cardiol. (2003) 26(2 Suppl. 2):II17-II20.
   Google Scholar
• FURBERG CD: A new era in hypertension research: discussing the findings of ALLHAT. Curr. Control Trials Cardiovasc. Med. (2001) 2(6):249-250.
   PubMedGoogle Scholar
• KAPLAN NM: The meaning of ALLHAT. J. Hypertens. (2003) 21(2):233-234.
   PubMed Web of Science ®Google Scholar
• MCINNES GT: ALLHAT: a saga of missed opportunities. J. Hum. Hypertens. (2003) 17(6):373-377.
   PubMed Web of Science ®Google Scholar
• ALDERMAN MH: ALLHAT and beyond. Am. J. Hypertens. (2003) 16(6):512-514.
   PubMed Web of Science ®Google Scholar
• MOSER M: Results of ALLHAT: is this the final answer regarding initial antihypertensive drug therapy? Arch. Intern. Med. (2003) 163(11):1269-1273.
   PubMed Web of Science ®Google Scholar
• FURBERG CD, PSATY BM, MEYER JV: Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation (1995) 92(5):1326-1331.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, WANG JG, THIJS L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (2001) 358(9290):1305-1315.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, WANG JG, THIJS L: Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am. J. Hypertens. (2002) 15(7 Pt 2):85S-93S.
   Google Scholar
• OPIE LH, SCHALL R: Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J. Am. Coll. Cardiol. (2002) 39(2):315-322.
   PubMed Web of Science ®Google Scholar
• OPIE LH: Calcium channel blockers in hypertension: reappraisal after new trials and major meta-analyses. Am. J. Hypertens. (2001) 14(10):1074-1081.
   PubMed Web of Science ®Google Scholar
• HENRY PD, BENTLEY KI: Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J. Clin. Invest. (1981) 68(5):1366-1369.
   PubMed Web of Science ®Google Scholar
• LICHTLEN PR, HUGENHOLTZ PG, RAFFLENBEUL W, HECKER H, JOST S, DECKERS JW: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet (1990) 335(8698):1109-1113.
   PubMed Web of Science ®Google Scholar
• LICHTLEN PR, HUGENHOLTZ PG, RAFFLENBEUL W et al.: Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy). Cardiovasc. Drugs Ther. (1990) 4(Suppl. 5):1047-1068.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, BOND MG, HENNIG M et al.: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation (2002) 106(19):2422-2427.
   PubMed Web of Science ®Google Scholar
• BORHANI NO, MERCURI M, BORHANI PA et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA (1996) 276(10):785-791.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, ROSEI EA, DAL PALU C, LEONETTI G, MAGNANI B, PESSINA A: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens. (1998) 16(11):1667-1676.
   PubMed Web of Science ®Google Scholar
• ROSEI EA, DAL PALU C, LEONETTI G, MAGNANI B, PESSINA A, ZANCHETTI A: Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. J. Hypertens. (1997) 15(11):1337-1344.
   PubMed Web of Science ®Google Scholar
• PITT B, BYINGTON RP, FURBERG CD et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 102(13):1503-1510.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, LIBBY P et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 292(18):2217-2225.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, PALMIERI V, SHARPE N et al.: Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation (2001) 104(11):1248-1254.
   PubMed Web of Science ®Google Scholar
• DAHLÖF B, PENNERT K, HANSSON L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens. (1992) 5(2):95-110.
   PubMed Web of Science ®Google Scholar
• CRUICKSHANK JM, LEWIS J, MOORE V, DODD C: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Hum. Hypertens. (1992) 6(2):85-90.
   PubMed Web of Science ®Google Scholar
• FAGARD RH: Reversibility of left ventricular hypertrophy by antihypertensive drugs. Neth. J. Med. (1995) 47(4):173-179.
   PubMed Web of Science ®Google Scholar
• BILGE AK, ATILGAN D, TUKEK T et al.: Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension. Int. J. Clin. Pract. (2005) 59(3):306-310.
   PubMed Web of Science ®Google Scholar
• LUKSA J, JOSIC D, PODOBNIK B, FURLAN B, KREMSER M: Semi-preparative chromatographic purification of the enantiomers S-(-)-amlodipine and R-(+)-amlodipine. J. Chromatogr. B Biomed. Sci. Appl. (1997) 693(2):367-375.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WH, ZUCKERMAN AL: Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev. Cardiovasc. Ther. (2004) 2(5):675-681.
   PubMedGoogle Scholar
• STIEBER J, HOFMANN F, LUDWIG A: Pacemaker channels and sinus node arrhythmia. Trends Cardiovasc. Med. (2004) 14(1):23-28.
   PubMed Web of Science ®Google Scholar
• STRIESSNIG J: Targeting voltage-gated Ca2+ channels. Lancet (2001) 357(9264):1294.
   PubMedGoogle Scholar
• CABO C, SCHMITT H, WIT AL: New mechanism of antiarrhythmic drug action: increasing L-type calcium current prevents reentrant ventricular tachycardia in the infarcted canine heart. Circulation (2000) 102(19):2417-2425.
   PubMed Web of Science ®Google Scholar
• DRAZNER MH: The transition from hypertrophy to failure: how certain are we? Circulation (2005) 112(7):936-938.
   PubMed Web of Science ®Google Scholar
• NATHAN S, PEPINE CJ, BAKRIS GL: Calcium antagonists: effects on cardio–renal risk in hypertensive patients. Hypertension (2005) 46(4):637-642.
   PubMed Web of Science ®Google Scholar
• MOTZ W, STRAUER BE: Nifedipine in the long-term management of hypertensive heart disease. Hypertension (1983) 5(4 Pt 2):II39-II44.
   Google Scholar
• CAMPBELL SE, TUREK Z, RAKUSAN K, KAZDA S: Cardiac structural remodelling after treatment of spontaneously hypertensive rats with nifedipine or nisoldipine. Cardiovasc. Res. (1993) 27(7):1350-1358.
   PubMed Web of Science ®Google Scholar
• KIM S, OHTA K, HAMAGUCHI A, YUKIMURA T, MIURA K, IWAO H: Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br. J. Pharmacol. (1996) 118(3):549-556.
   PubMed Web of Science ®Google Scholar
• KYSELOVIC J, KRENEK P, WIBO M, GODFRAIND T: Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Br. J. Pharmacol. (2001) 134(7):1516-1522.
   PubMed Web of Science ®Google Scholar
• SUSIC D, VARAGIC J, FROHLICH ED: Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J. Hypertens. (1999) 17(8):1209-1215.
   PubMed Web of Science ®Google Scholar
• NARUSE M, TANABE A, SEKI T et al.: Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats. J. Hypertens. (1999) 17(1):53-60.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, TANIKAWA S, TAKAHASHI K: Protective effects of CD-832 on organ damage in stroke-prone spontaneously hypertensive rats. Eur. J. Pharmacol. (1997) 331(2-3):193-198.
   PubMed Web of Science ®Google Scholar
• CARAFOLI E, BRINI M: Calcium pumps: structural basis for and mechanism of calcium transmembrane transport. Curr. Opin. Chem. Biol. (2000) 4(2):152-161.
   PubMed Web of Science ®Google Scholar
• BRINI M, CARAFOLI E: Calcium signalling: a historical account, recent developments and future perspectives. Cell Mol. Life Sci. (2000) 57(3):354-370.
   PubMed Web of Science ®Google Scholar
• BRINI M, COLETTO L, PIEROBON N, KRAEV N, GUERINI D, CARAFOLI E: A comparative functional analysis of plasma membrane Ca2+ pump isoforms in intact cells. J. Biol. Chem. (2003) 278(27):24500-24508.
   PubMed Web of Science ®Google Scholar
• BERRIDGE MJ, LIPP P, BOOTMAN MD: The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. (2000) 1(1):11-21.
   PubMed Web of Science ®Google Scholar
• BOOTMAN MD, LIPP P, BERRIDGE MJ: The organisation and functions of local Ca(2+) signals. J. Cell Sci. (2001) 114(Pt 12):2213-2222.
   PubMed Web of Science ®Google Scholar
• BERRIDGE MJ, LIPP P, BOOTMAN MD: Signal transduction. The calcium entry pas de deux. Science (2000) 287(5458):1604-1605.
   PubMed Web of Science ®Google Scholar
• PETERSEN OH, BURDAKOV D, TEPIKIN AV: Polarity in intracellular calcium signaling. Bioessays (1999) 21(10):851-860.
   PubMed Web of Science ®Google Scholar
• PETERSEN OH, TEPIKIN A, PARK MK: The endoplasmic reticulum: one continuous or several separate Ca(2+) stores? Trends Neurosci. (2001) 24(5):271-276.
   PubMed Web of Science ®Google Scholar
• MOLKENTIN JD, DORN IG 2nd: Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Ann. Rev. Physiol. (2001) 63:391-426.
   PubMed Web of Science ®Google Scholar
• FREY N, MCKINSEY TA, OLSON EN: Decoding calcium signals involved in cardiac growth and function. Nat. Med. (2000) 6(11):1221-1227.
   PubMed Web of Science ®Google Scholar
• ISENBERG G: Ca2+ control of transcription: can we extrapolate signaling cascades from neurons to vascular smooth muscle cells? Circ. Res. (2004) 94(10):1276-1278.
   PubMed Web of Science ®Google Scholar
• WILKINS BJ, MOLKENTIN JD: Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. (2004) 322(4):1178-1191.
   PubMed Web of Science ®Google Scholar
• WILKINS BJ, DAI YS, BUENO OF et al.: Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. (2004) 94(1):110-118.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T: Calcium antagonists and vasodilatation. Pharmacol. Ther. (1994) 64(1):37-75.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T, MILLER RC: Specificity of action of Ca++ entry blockers. A comparison of their actions in rat arteries and in human coronary arteries. Circ. Res. (1983) 52(2 Pt 2):I81-I91.
   Web of Science ®Google Scholar
• GODFRAIND T: Cardioselectivity of calcium antagonists. Cardiovasc. Drugs Ther. (1994) 8(Suppl. 2):353-364.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T, SALOMONE S, DESSY C, VERHELST B, DION R, SCHOEVAERTS JC: Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J. Cardiovasc. Pharmacol. (1992) 20(Suppl. 5):S34-S41.
   PubMed Web of Science ®Google Scholar
• SARSERO D, FUJIWARA T, MOLENAAR P, ANGUS JA: Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists. Br. J. Pharmacol. (1998) 125(1):109-119.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T: Actions of nifedipine on calcium fluxes and contraction in isolated rat arteries. J. Pharmacol. Exp. Ther. (1983) 224(2):443-450.
   PubMed Web of Science ®Google Scholar
• MOREL N, BURYI V, FERON O, GOMEZ JP, CHRISTEN MO, GODFRAIND T: The action of calcium channel blockers on recombinant L-type calcium channel α1-subunits. Br. J. Pharmacol. (1998) 125(5):1005-1012.
   PubMed Web of Science ®Google Scholar
• DE PAOLI P, CERBAI E, KOIDL B, KIRCHENGAST M, SARTIANI L, MUGELLI A: selectivity of different calcium antagonists on T- and L-type calcium currents in guinea-pig ventricular myocytes. Pharmacol. Res. (2002) 46(6):491-497.
   PubMed Web of Science ®Google Scholar
• FURUKAWA T, NUKADA T, SUZUKI K, FUJITA Y, MORI Y, NISHIMURA M et al.: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br. J. Pharmacol. (1997) 121(6):1136-1140.
   PubMed Web of Science ®Google Scholar
• BÉNARDEAU A, ERTEL EA: Selective block of myocardial T-type calcium channels by mibefradil: a comparison with the 1,4-dihydropyridine amlodipine. In: Low-voltage-activated t-type Ca channels. RW Tsien, JP Clozel, J Nargeot (Eds), Adis International, Chester, UK (1998):386-394.
   Google Scholar
• XU B, XIAO-HONG L, LIN G, QUEEN L, FERRO A: Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br. J. Pharmacol. (2002) 136(3):375-382.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T, SALOMONE S: Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc. Drugs Ther. (1996) 10(4):439-446.
   PubMed Web of Science ®Google Scholar
• SALOMONE S, SILVA CL, MOREL N, GODFRAIND T: Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch. Pharmacol. (1996) 354(4):505-512.
   PubMed Web of Science ®Google Scholar
• UNEYAMA H, UCHIDA H, KONDA T, YOSHIMOTO R, AKAIKE N: Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels. Eur. J. Pharmacol. (1999) 373(1):93-100.
   PubMed Web of Science ®Google Scholar
• WELLING A, LUDWIG A, ZIMMER S, KLUGBAUER N, FLOCKERZI V, HOFMANN F: Alternatively spliced IS6 segments of the α1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2+ channels. Circ. Res. (1997) 81(4):526-532.
   PubMed Web of Science ®Google Scholar
• YATANI A, KUNZE DL, BROWN AM: Effects of dihydropyridine calcium channel modulators on cardiac sodium channels. Am. J. Physiol. (1988) 254(1 Pt 2):H140-H147.
   PubMed Web of Science ®Google Scholar
• TERLAND O, FLATMARK T: Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles. Neuropharmacology (1999) 38(6):879-882.
   PubMed Web of Science ®Google Scholar
• GRACE AA, CAMM AJ: Voltage-gated calcium-channels and antiarrhythmic drug action. Cardiovasc. Res. (2000) 45(1):43-51.
   PubMed Web of Science ®Google Scholar
• HATANO N, OHYA S, MURAKI K, GILES W, IMAIZUMI Y: Dihydropyridine Ca(2+) channel antagonists and agonists block Kv4.2, Kv4.3 and Kv1.4 K(+) channels expressed in HEK293 cells. Br. J. Pharmacol. (2003) 139(3):533-544.
   PubMed Web of Science ®Google Scholar
• BECKER RH, LINZ W, WIEMER G, NORDLANDER M: Low-dose felodipine treatment attenuates endothelial dysfunction in rabbits fed an atherogenic diet. J. Cardiovasc. Pharmacol. (1991) 18(Suppl. 10):S36-S41.
   PubMed Web of Science ®Google Scholar
• HABIB J, BOSSALLER C, WELLS S, WILLIAMS C, MORRISETT J, HENRY P: Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN-200110. Circ. Res. (1986) 58:305-309.
   PubMed Web of Science ®Google Scholar
• MONCADA S, MARTIN JF, HIGGS A: Symposium on regression of atherosclerosis. Eur. J. Clin. Invest. (1993) 23(7):385-398.
   PubMed Web of Science ®Google Scholar
• MONCADA S, HIGGS A: The l-arginine-nitric oxide pathway. N. Engl. J. Med. (1993) 329(27):2002-2012.
   PubMed Web of Science ®Google Scholar
• BROVKOVYCH VV, KALINOWSKI L, MULLER-PEDDINGHAUS R, MALINSKI T: Synergistic antihypertensive effects of nifedipine on endothelium: concurrent release of NO and scavenging of superoxide. Hypertension (2001) 37(1):34-39.
   PubMed Web of Science ®Google Scholar
• ZHANG X, HINTZE TH: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation (1998) 97(6):576-580.
   PubMed Web of Science ®Google Scholar
• ZHANG XP, LOKE KE, MITAL S, CHAHWALA S, HINTZE TH: Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J. Cardiovasc. Pharmacol. (2002) 39(2):208-214.
   PubMed Web of Science ®Google Scholar
• ZHANG X, RECCHIA FA, BERNSTEIN R, XU X, NASJLETTI A, HINTZE TH: Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. J. Pharmacol. Exp. Ther. (1999) 288(2):742-751.
   PubMed Web of Science ®Google Scholar
• ZHANG X, KICHUK MR, MITAL S et al.: Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am. J. Cardiol. (1999) 84(4A):27L-33L.
   Google Scholar
• DING Y, VAZIRI ND: Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension (1998) 32(4):718-723.
   PubMed Web of Science ®Google Scholar
• WANG XQ, VAZIRI ND: Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension (1999) 33(3):894-899.
   PubMed Web of Science ®Google Scholar
• KRENEK P, SALOMONE S, KYSELOVIC J, WIBO M, MOREL N, GODFRAIND T: Lacidipine prevents endothelial dysfunction in salt-loaded stroke-prone hypertensive rats. Hypertension (2001) 37(4):1124-1128.
   PubMed Web of Science ®Google Scholar
• TADDEI S, VIRDIS A, GHIADONI L et al.: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension (2001) 37(3):943-948.
   PubMed Web of Science ®Google Scholar
• TADDEI S, VIRDIS A, GHIADONI L et al.: Effect of calcium antagonist or β-blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J. Hypertens. (2001) 19(8):1379-1386.
   PubMed Web of Science ®Google Scholar
• NAPOLI C, CHIARIELLO M, PALUMBO G, AMBROSIO G: Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals. Cardiovasc. Drugs Ther. (1996) 10(4):417-424.
   PubMed Web of Science ®Google Scholar
• ROJSTACZER N, TRIGGLE DJ: Structure–function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein. Biochem. Pharmacol. (1996) 51(2):141-150.
   PubMed Web of Science ®Google Scholar
• SOBALA G, MENZEL EJ, SINZINGER H: Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem. Pharmacol. (2001) 61(3):373-379.
   PubMed Web of Science ®Google Scholar
• ZALBA G, SAN JOSE G, MORENO MU et al.: Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension (2001) 38(6):1395-1399.
   PubMed Web of Science ®Google Scholar
• NAKAZONO K, WATANABE N, MATSUNO K, SASAKI J, SATO T, INOUE M: Does superoxide underlie the pathogenesis of hypertension? Proc. Natl. Acad. Sci. USA (1991) 88(22):10045-10048.
   PubMed Web of Science ®Google Scholar
• GRIENDLING KK, SORESCU D, USHIO-FUKAI M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. (2000) 86(5):494-501.
   PubMed Web of Science ®Google Scholar
• TOIKKA JO, LAINE H, AHOTUPA M et al.: Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension (2000) 36(6):929-933.
   PubMed Web of Science ®Google Scholar
• IRANI K: Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. (2000) 87(3):179-183.
   PubMed Web of Science ®Google Scholar
• BRASIER AR, LI J: Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension (1996) 27(3 Pt 2):465-475.
   PubMed Web of Science ®Google Scholar
• LUFT FC: Angiotensin, inflammation, hypertension and cardiovascular disease. Curr. Hypertens. Rep. (2001) 3(1):61-67.
   PubMedGoogle Scholar
• LUFT FC: Workshop: mechanisms and cardiovascular damage in hypertension. Hypertension (2001) 37(2 Part 2):594-598.
   PubMed Web of Science ®Google Scholar
• MASON RP: Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis (2002) 165(2):191-199.
   PubMed Web of Science ®Google Scholar
• URSINI F: Tissue protection by lacidipine: insight from redox behavior. J. Cardiovasc. Pharmacol. (1997) 30(Suppl. 2):S28-S30.
   Google Scholar
• NAPOLI C, SALOMONE S, GODFRAIND T et al.: 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke (1999) 30(9):1907-1915.
   PubMed Web of Science ®Google Scholar
• BERKELS R, EGINK G, MARSEN TA, BARTELS H, ROESEN R, KLAUS W: Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension (2001) 37(2):240-245.
   PubMed Web of Science ®Google Scholar
• COMINACINI L, GARBIN U, FRATTA PASINI A et al.: Lacidipine inhibits the activation of the transcription factor NF-κB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J. Hypertens. (1997) 15(12 Pt 2):1633-1640.
   PubMed Web of Science ®Google Scholar
• CRISTOFORI P, LANZONI A, QUARTAROLI M et al.: The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J. Hypertens. (2000) 18(10):1429-1436.
   PubMed Web of Science ®Google Scholar
• LEONETTI G, CUSPIDI C, SAMPIERI L, TERZOLI L, ZANCHETTI A: Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. J. Cardiovasc. Pharmacol. (1982) 4(Suppl 3):S319-S324.
   PubMed Web of Science ®Google Scholar
• KNORR A, GARTHOFF B: Differential influence of the calcium antagonist nitrendipine and the vasodilator hydralazine on normal and elevated blood pressure. Arch. Int. Pharmacodyn. Ther. (1984) 269(2):316-322.
   PubMedGoogle Scholar
• MOREL N, GODFRAIND T: Selective interaction of the calcium antagonist amlodipine with calcium channels in arteries of spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (1994) 24(4):524-533.
   PubMed Web of Science ®Google Scholar
• LIU Y, PLEYTE K, KNAUS HG, RUSCH NJ: Increased expression of Ca2+-sensitive K+ channels in aorta of hypertensive rats. Hypertension (1997) 30(6):1403-1409.
   PubMed Web of Science ®Google Scholar
• ASANO M, MATSUDA T, HAYAKAWA M, ITO KM, ITO K: Increased resting Ca2+ maintains the myogenic tone and activates K+ channels in arteries from young spontaneously hypertensive rats. Eur. J. Pharmacol. (1993) 247(3):295-304.
   PubMed Web of Science ®Google Scholar
• COX RH, RUSCH NJ: New expression profiles of voltage-gated ion channels in arteries exposed to high blood pressure. Microcirculation (2002) 9(4):243-257.
   PubMed Web of Science ®Google Scholar
• ASANO M, NOMURA Y, ITO K, UYAMA Y, IMAIZUMI Y, WATANABE M: Increased function of voltage-dependent Ca++ channels and Ca(++)-activated K+ channels in resting state of femoral arteries from spontaneously hypertensive rats at prehypertensive stage. J. Pharmacol. Exp. Ther. (1995) 275(2):775-783.
   PubMed Web of Science ®Google Scholar
• JACKSON WF: Ion channels and vascular tone. Hypertension (2000) 35(1 Pt 2):173-178.
   PubMed Web of Science ®Google Scholar
• PRATT PF, BONNET S, LUDWIG LM, BONNET P, RUSCH NJ: Upregulation of l-type Ca2+ channels in mesenteric and skeletal arteries of SHR. Hypertension (2002) 40(2):214-219.
   PubMed Web of Science ®Google Scholar
• MESSERLI F, SCHMIEDER RE, WEIR MR: Salt. A perpetrator of hypertensive target organ disease? Arch. Intern. Med. (1997) 157:2449-2452.
   PubMed Web of Science ®Google Scholar
• KYSELOVIC J, MOREL N, WIBO M, GODFRAIND T: Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. J. Hypertens. (1998) 16(10):1515-1522.
   PubMed Web of Science ®Google Scholar
• ARRIBAS SM, COSTA R, SALOMONE S, MOREL N, GODFRAIND T, MCGRATH JC: Functional reduction and associated cellular rearrangement in SHRSP rat basilar arteries are affected by salt load and calcium antagonist treatment. J. Cereb. Blood Flow Metab. (1999) 19(5):517-527.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T, SALOMONE S, MOREL N, GHISDAL P: [Preclinical study of the action of a calcium channel blocker during salt load]. Bull. Acad. Natl. Med. (1997) 181(2):289-298; discussion 299-300.
   PubMed Web of Science ®Google Scholar
• SALOMONE S, DESSY C, MOREL N, GODFRAIND T: Inhibition by bosentan, an endothelin antagonist, of the hypersensitivity to Ca2+ channel activator evoked by salt-loading in basilar artery of stroke-prone spontaneously hypertensive rats. Life Sci. (1996) 59(16):PL247-PL253.
   Google Scholar
• HENRY PD: Atherogenesis, calcium and calcium antagonists. Am. J. Cardiol. (1990) 66(21):3I-6I.
   Google Scholar
• TULENKO TN, SUMNER AE, CHEN M, HUANG Y, LAURY-KLEINTOP L, FERDINAND FD: The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am. Heart J. (2001) 141(2 Suppl.):S1-S11.
   PubMedGoogle Scholar
• HANSSON GK, EDFELDT K: Toll to be paid at the gateway to the vessel wall. Arterioscler. Thromb. Vasc. Biol. (2005) 25(6):1085-1087.
   PubMed Web of Science ®Google Scholar
• DZAU VJ, BRAUN-DULLAEUS RC, SEDDING DG: Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. (2002) 8(11):1249-1256.
   PubMed Web of Science ®Google Scholar
• LIBBY P: Molecular bases of the acute coronary syndrome. Circulation (1995) 91:2844-2850.
   PubMed Web of Science ®Google Scholar
• HENRY P: Atherosclerosis, calcium and calcium antagonists. Circulation (1985) 72:456-459.
   PubMedGoogle Scholar
• PAOLETTI R, CORSINI A, SOMA MR, BERNINI F: Calcium, calcium antagonists and experimental atherosclerosis. Blood Press. Suppl. (1996) 4:12-15.
   PubMedGoogle Scholar
• SOMA MR, DONETTI E, PAROLINI C et al.: Effect of lacidipine on the carotid intimal hyperplasia induced by cuff injury. J. Cardiovasc. Pharmacol. (1994) 23(Suppl. 5):S71-S74.
   PubMed Web of Science ®Google Scholar
• SOMA MR, DONETTI E, SEREGNI R et al.: Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. Br. J. Pharmacol. (1996) 118(2):215-219.
   PubMed Web of Science ®Google Scholar
• DONETTI E, FUMAGALLI R, PAOLETTI R, SOMA MR: Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits. Pharmacol. Res. (1997) 35(5):417-422.
   PubMed Web of Science ®Google Scholar
• WILLIS AL, NAGEL B, CHURCHILL V et al.: Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis (1985) 5(3):250-255.
   PubMedGoogle Scholar
• LICHTOR T, DAVIS HR, VESSELINOVITCH D, WISSLER RW, MULLAN S: Suppression of atherogenesis by nifedipine in the cholesterol-fed rhesus monkey. Appl. Pathol. (1989) 7(1):8-18.
   PubMedGoogle Scholar
• BOSSALLER C, HABIB GB, YAMAMOTO H, WILLIAMS C, WELLS S, HENRY PD: Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J. Clin. Invest. (1987) 79(1):170-174.
   PubMed Web of Science ®Google Scholar
• HABIB JB, BOSSALLER C, WELLS S, WILLIAMS C, MORRISETT JD, HENRY PD: Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ. Res. (1986) 58(2):305-309.
   PubMed Web of Science ®Google Scholar
• PRATICO D, TANGIRALA RK, RADER DJ, ROKACH J, FITZGERALD GA: Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med. (1998) 4(10):1189-1192.
   PubMed Web of Science ®Google Scholar
• THOMAS SR, LEICHTWEIS SB, PETTERSSON K et al.: Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler. Thromb. Vasc. Biol. (2001) 21(4):585-593.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA Y, PLUMP AS, RAINES EW, BRESLOW JL, ROSS R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. (1994) 14:133-140.
   PubMed Web of Science ®Google Scholar
• BARTON M, HAUDENSCHILD CC, D’USCIO LV, SHAW S, MUNTER K, LUSCHER TF: Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95(24):14367-14372.
   PubMed Web of Science ®Google Scholar
• D’USCIO LV, BAKER TA, MANTILLA CB et al.: Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2001) 21(6):1017-1022.
   PubMed Web of Science ®Google Scholar
• PLUMP AS, SMITH JD, HAYEK T et al.: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell (1992) 71(2):343-353.
   PubMed Web of Science ®Google Scholar
• BONTHU S, HEISTAD DD, CHAPPELL DA, LAMPING KG, FARACI FM: Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler. Thromb. Vasc. Biol. (1997) 17(11):2333-2340.
   PubMed Web of Science ®Google Scholar
• BARTON M, HAUDENSCHILD CC: Endothelium and atherogenesis: endothelial therapy revisited. J. Cardiovasc. Pharmacol. (2001) 38(Suppl. 2):S23-S25.
   PubMedGoogle Scholar
• LIBBY P, GALIS ZS: Cytokines regulate genes involved in atherogenesis. Ann. NY Acad. Sci. (1995) 748:158-168; discussion 168-170.
   PubMed Web of Science ®Google Scholar
• LIBBY P, SUKHOVA G, LEE RT, GALIS ZS: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J. Cardiovasc. Pharmacol. (1995) 25(Suppl. 2):S9-S12.
   PubMedGoogle Scholar
• HAYEK T, OIKNINE J, BROOK JG, AVIRAM M: Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem. Biophys. Res. Commun. (1994) 201(3):1567-1574.
   PubMed Web of Science ®Google Scholar
• JIANG F, GIBSON AP, DUSTING GJ: Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice. Eur. J. Pharmacol. (2001) 424(2):141-149.
   PubMed Web of Science ®Google Scholar
• LU X, KASSAB GS: Nitric oxide is significantly reduced in ex-vivo porcine arteries during reverse flow because of increased superoxide production. J. Physiol. (2004) 561(Pt 2):575-582.
   Google Scholar
• KYSELOVIC J, MARTINKA P, BATOVA Z, GAZOVA A, GODFRAIND T: Calcium channel blocker inhibits western-type diet-evoked atherosclerosis development in ApoE-deficient mice. J. Pharmacol. Exp. Ther. (2005) 315(1):320-328.
   PubMed Web of Science ®Google Scholar
• UNEYAMA H, UCHIDA H, KONDA T, YOSIMOTO R: Cilnidipine: preclinical profile and clinical evaluation. Cardiovasc. Drug Rev. (1999) 17(4):341-357.
   Google Scholar
• POOLE-WILSON PA, LUBSEN J, KIRWAN BA et al.: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 364(9437):849-857.
   PubMed Web of Science ®Google Scholar
• NORDLANDER M, SJOQUIST PO, ERICSSON H, RYDEN L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc. Drug Rev. (2004) 22(3):227-250.
   PubMed Web of Science ®Google Scholar
• LIANG JC, YEH JL, WANG CS, LIOU SF, TSAI CH, CHEN IJ: The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display α-/β-adrenoceptor antagonist and long-acting antihypertensive activities. Bioorg. Med. Chem. (2002) 10(3):719-730.
   PubMed Web of Science ®Google Scholar
• LIOU SF, YEH JL, LIANG JC, CHIU CC, LIN YT, CHEN IJ: Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway. J. Cardiovasc. Pharmacol. (2004) 44(5):539-551.
   PubMed Web of Science ®Google Scholar
• SHAN R, VELAZQUEZ C, KNAUS EE: Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-ca rboxylate racemates, enantiomers, and diastereomers. J. Med. Chem. (2004) 47(1):254-261.
   PubMed Web of Science ®Google Scholar
• GORDEEV MF, PATEL DV, ENGLAND BP, JONNALAGADDA S, COMBS JD, GORDON EM: Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers. Bioorg. Med. Chem. (1998) 6(7):883-889.
   PubMed Web of Science ®Google Scholar
• WILLUMSEN NJ, BECH M, OLESEN SP, JENSEN BS, KORSGAARD MP, CHRISTOPHERSEN P: High throughput electrophysiology: new perspectives for ion channel drug discovery. Receptors Channels (2003) 9(1):3-12.
   PubMedGoogle Scholar
• CARD GL, BLASDEL L, ENGLAND BP et al.: A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol. (2005) 23(2):201-207.
   PubMed Web of Science ®Google Scholar
• MISSAN S, ZHABYEYEV P, DYACHOK O, JONES SE, MCDONALD TF: Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine. Br. J. Pharmacol. (2003) 140(5):863-870.
   PubMed Web of Science ®Google Scholar
• JONES SE, MISSAN S, ZHABYEYEV P, MCDONALD TF: Selective phenylalkylamine block of I(Kr) over other K(+) currents in guinea-pig ventricular myocytes. Br. J. Pharmacol. (2000) 131(8):1809-1816.
   PubMed Web of Science ®Google Scholar
• ZHABYEYEV P, MISSAN S, JONES SE, MCDONALD TF: Low-affinity block of cardiac K(+) currents by nifedipine. Eur. J. Pharmacol. (2000) 401(2):137-143.
   PubMed Web of Science ®Google Scholar
• NISHIMURA J, KANAIDE H, NAKAMURA M: Binding of [3H]prazosin to porcine aortic membranes: interaction of calcium antagonists with vascular α-1 adrenoceptors. J. Pharmacol. Exp. Ther. (1986) 236(3):789-793.
   PubMed Web of Science ®Google Scholar
• ROGER S, LE GUENNEC JY, BESSON P: Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line. Br. J. Pharmacol. (2004) 141(4):610-615.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T, KABA A: Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br. J. Pharmacol. (1969) 36(3):549-560.
   PubMed Web of Science ®Google Scholar
• JAMERSON KA, BAKRIS GL, WUN CC et al.: Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am. J. Hypertens. (2004) 17(9):793-801.
   PubMed Web of Science ®Google Scholar
• SEVER PS, DAHLÖF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361(9364):1149-1158.
   PubMed Web of Science ®Google Scholar
• DAHLÖF B, SEVER PS, POULTER NR et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366(9489):895-906.
   PubMed Web of Science ®Google Scholar
• ENCORE INVESTIGATORS: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation (2003) 107(3):422-428.
   PubMed Web of Science ®Google Scholar
• BROWN MJ, PALMER CR, CASTAIGNE A et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet (2000) 356(9227):366-372.
   PubMed Web of Science ®Google Scholar
• PEPINE CJ, HANDBERG EM, COOPER-DEHOFF RM et al.: A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA (2003) 290(21):2805-2816.
   PubMed Web of Science ®Google Scholar
• SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36(6):1218-1226.
   PubMed Web of Science ®Google Scholar
• DENS JA, DESMET WJ, COUSSEMENT P et al.: Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart (2003) 89(8):887-892.
   PubMed Web of Science ®Google Scholar
• HANSSON L, HEDNER T, LUNDHJOHANSEN P et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet (2000) 356(9227):359-365.
   PubMed Web of Science ®Google Scholar
• MALACCO E, MANCIA G, RAPPELLI A, MENOTTI A, ZUCCARO MS, COPPINI A: Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. (2003) 12(3):160-167.
   PubMed Web of Science ®Google Scholar
• GONG L, ZHANG W, ZHU Y et al.: Shanghai trial of nifedipine in the elderly (STONE). J. Hypertens. (1996) 14(10):1237-1245.
   PubMed Web of Science ®Google Scholar
• WANG JG, LIU G, WANG X et al.: Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J. Hum. Hypertens. (1996) 10(11):735-742.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, FAGARD R, THIJS L et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 350(9080):757-764.
   PubMed Web of Science ®Google Scholar
• JULIUS S, KJELDSEN SE, BRUNNER H et al.: VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. (2003) 16(7):544-548.
   PubMed Web of Science ®Google Scholar